Printer Friendly

TELA Bio to receive Series B Investment from Checkmate Capital.

BANKING AND CREDIT NEWS-April 26, 2018-TELA Bio to receive Series B Investment from Checkmate Capital


TELA Bio, Inc., a surgical reconstruction company, has announced that investment group Checkmate Capital, based in Los Angeles, California and Beijing, China, has agreed to an initial Series B investment in TELA Bio., the company said.

TELA Bio is engaged in the development and commercialization of OviTex Reinforced BioScaffolds (RBSs) for soft tissue repair,

Checkmate said with its historic and specific interest in cutting-edge biotech and biomedical technology, it is particularly enthusiastic about the scientific and commercial advances TELA Bio continues to achieve.

Checkmate Capital is an investment group managing family office assets and Asian-Pacific institutional funds. Checkmate's primary areas of investment are biomedical and biotechnology, energy and energy technology, and diversified special situations opportunities.

TELA Bio, Inc. is focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients. The company's OviTex Reinforced BioScaffolds (RBSs) products, designed for hernia repair and abdominal wall reconstruction procedures, integrate polymer and biologic materials in a uniquely embroidered construction using novel engineering design principles.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Banking & Credit News (BCN)
Date:Apr 26, 2018
Previous Article:Big Shoulders Capital completes sale of Anderson Manufacturing.
Next Article:Mogo approved for NASDAQ Capital Market listing.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters